RAPIVAB (bioCSL Inc.)
Welcome to the PulseAid listing for the RAPIVAB drug offered from bioCSL Inc.. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | bioCSL Inc. |
NON-PROPRIETARY NAME: | Peramivir |
SUBSTANCE NAME: | PERAMIVIR |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2014-12-20 |
END MARKETING DATE: | 0000-00-00 |
RAPIVAB HUMAN PRESCRIPTION DRUG Details:
Item Description | RAPIVAB from bioCSL Inc. |
LABELER NAME: | bioCSL Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 600(mg/60mL) |
START MARKETING DATE: | 2014-12-20 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 61364-181_81cacc91-52f2-43ce-a883-41352b1bbed3 |
PRODUCT NDC: | 61364-181 |
APPLICATION NUMBER: | NDA206426 |
Other PERAMIVIR Pharmaceutical Manufacturers / Labelers: